BioNTech (NASDAQ:BNTX) Hits New 52-Week Low at $103.70

Shares of BioNTech SE (NASDAQ:BNTX – Get Rating) hit a new 52-week low during trading on Tuesday . The stock traded as low as $103.70 and last traded at $104.66, with a volume of 188860 shares. The stock had previously closed at $108.05.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Jefferies Financial Group set a $145.00 price target on shares of BioNTech in a research note on Tuesday, March 28th. Morgan Stanley decreased their price target on shares of BioNTech from $216.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Tuesday, March 28th. The Goldman Sachs Group set a $140.00 target price on shares of BioNTech and gave the company a “neutral” rating in a research report on Tuesday, March 28th. TD Cowen cut their price target on shares of BioNTech from $145.00 to $130.00 and set a “market perform” rating on the stock in a report on Tuesday, March 28th. Finally, TheStreet downgraded shares of BioNTech from a “b-” rating to a “c+” rating in a report on Monday, March 27th. Seven research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $177.50.

BioNTech Price Performance

The stock’s 50-day moving average is $122.94 and its 200 day moving average is $141.87. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.43 and a quick ratio of 7.28. The company has a market cap of $24.95 billion, a PE ratio of 2.58 and a beta of 0.21.

BioNTech (NASDAQ:BNTX – Get Rating) last posted its earnings results on Monday, May 8th. The company reported $2.05 EPS for the quarter, beating analysts’ consensus estimates of $0.18 by $1.87. BioNTech had a net margin of 54.61% and a return on equity of 53.36%. The company had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.09 billion. During the same quarter in the prior year, the company posted $15.98 earnings per share. BioNTech’s revenue for the quarter was down 80.0% compared to the same quarter last year. On average, equities analysts anticipate that BioNTech SE will post 4.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioNTech

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. raised its holdings in shares of BioNTech by 23.2% in the third quarter. Assenagon Asset Management S.A. now owns 10,881 shares of the company’s stock worth $1,468,000 after buying an additional 2,052 shares during the last quarter. Baldwin Brothers LLC MA raised its holdings in shares of BioNTech by 33.9% in the fourth quarter. Baldwin Brothers LLC MA now owns 648 shares of the company’s stock worth $97,000 after buying an additional 164 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of BioNTech by 32.2% in the third quarter. Envestnet Asset Management Inc. now owns 19,450 shares of the company’s stock worth $2,623,000 after buying an additional 4,742 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. purchased a new position in shares of BioNTech in the fourth quarter worth $107,000. Finally, Pacer Advisors Inc. raised its holdings in shares of BioNTech by 162.8% in the fourth quarter. Pacer Advisors Inc. now owns 1,009 shares of the company’s stock worth $152,000 after buying an additional 625 shares during the last quarter. Hedge funds and other institutional investors own 15.29% of the company’s stock.

BioNTech Company Profile

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.